Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

October 14, 2020October 14, 2020

FDA Approves Clinical Trial of TIVUS System in PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has granted SoniVie permission to begin a pivotal clinical trial of its Therapeutic Intra-Vascular Ultrasound (TIVUS) System in people with pulmonary arterial hypertension ... Read more

September 18, 2020September 18, 2020

Study Results Support Opsumit-Adcirca Combo for Newly Diagnosed PAH

News, PAH News

The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary arterial hypertension (PAH), new clinical trial data show. The findings were published ... Read more

August 21, 2020August 21, 2020

FDA Reviewing Application for Tyvaso as Treatment for PH-ILD

News, PH News

The U.S. Food and Drug Administration (FDA) has accepted for review the application for Tyvaso (inhaled treprostinil) as a potential treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The ... Read more

August 3, 2020August 3, 2020

PVR Threshold for Mortality Risk Lower Than Previously Thought, Study Suggests

News

High pulmonary vascular resistance (PVR) is associated with worse mortality rates among people with pulmonary hypertension (PH), and the bottom threshold for what constitutes “elevated” PVR is lower than previously thought, ... Read more

July 27, 2020July 27, 2020

Outcomes Better for PAH Patients Treated at Specialty Centers, Study Finds

News, PAH News

People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support ... Read more

July 13, 2020July 13, 2020

Certain US Veterans More Likely to be Inappropriately Prescribed PDE5 Inhibitors

News

U.S. veterans with pulmonary hypertension (PH) due to left heart disease and chronic lung disease are more likely to be inappropriately prescribed phosphodiesterase-5 inhibitors (PDE5i) if they have received ... Read more

May 11, 2020May 11, 2020

At-home System of Inhaled Nitric Oxide Treats PAH Patient Infected With COVID-19

News, PAH News

At-home treatment with inhaled nitric oxide through Genosyl, a tankless delivery system, was used successfully to manage pulmonary arterial hypertension (PAH) complicated by COVID-19 in a patient, according to a ... Read more

May 1, 2020May 1, 2020

LIQ861, Inhaled Form of Treprostinil, Fares Well in Phase 3 Trial for PAH

News

LIQ861, Liquidia Technology‘s investigational inhaled formulation of treprostinil, is safe and well-tolerated in patients with pulmonary arterial hypertension (PAH), according to final results from a Phase 3 clinical trial. ... Read more

April 29, 2020April 29, 2020

Pulmonary Hypertension Association to Hold Virtual Fundraiser on World PH Day

News, PH News

The Pulmonary Hypertension Association (PHA) will be participating in a fundraiser for World PH Day on May 5. World PH Day is an annual event that started in 2012 ... Read more

April 1, 2020April 1, 2020

Reata Stops Bardoxolone PAH Trials Amid COVID-19 Concerns

News, PAH News

Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including a Phase 3 study, to ensure the safety of participants during the ... Read more

Pin It on Pinterest